Angiogenesis and vascular endothelial growth factors in intraocular tumors

Developments in Ophthalmology

Volumn 46, Issue , 2010, Pages 123-132

  Missotten, Guy S ^a,b   Schlingemann, Reinier O ^b   Jager, Martine J ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GLUCOCORTICOID; MONOCLONAL ANTIBODY; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN A;

ANIMAL; ARTICLE; CHRONIC DISEASE; EYE TUMOR; HUMAN; INFLAMMATION; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; METASTASIS; NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); RADIATION INJURY; RETINA DISEASE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; EYE NEOPLASMS; GLAUCOMA, NEOVASCULAR; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; INJECTIONS, INTRAOCULAR; NEOVASCULARIZATION, PATHOLOGIC; RADIATION INJURIES; RETINAL DISEASES; TRIAMCINOLONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84925933663     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000320015     Document Type: Article

References (60)

1. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM: Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988;32:239-251.
2. Folkman J: Tumour angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
3. Verheul HM, Voest EE, Schlingemann RO: Are tumours angiogenesis- dependent? J Pathol 2004;202:5-13.
4. Foss AJ, Alexander RA, Jefferies LW, Hungerford JL, Harris AL, Lightman S: Microvessel count predicts survival in uveal melanoma. Cancer Res 1996;56:2900-2903.
5. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci 1999;40:2471-2480.
6. Pina Y, Boutrid H, Schefler A, Dubovy S, Feuer W, Jockovich ME, Murray TG: Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. Invest Ophthalmol Vis Sci 2009;50:1020-1024.
7. Pina Y, Cebulla CM, Murray TG, Alegret A, Dubovy SR, Boutrid H, Feuer W, Mutapcic L, Jockovich ME: Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. Ophthalmic Res 2009;41:160-169.
8. Witmer AN, Vrensen GF, van Noorden CJ, Schlingemann RO: Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
9. Missotten GS: Doctoral Thesis. Angiogenesis and Screening in Uveal Melanoma. Leiden, The Netherlands, 2005.
10. Kvanta A, Steen B, Seregard S: Expression of VEGF in retinoblastoma but not in posterior uveal melanoma. Exp Eye Res 1996;63:511-518.
11. Stitt AW, Simpson DA, Boocock C, Gardiner TA, Murphy GM, Archer DB: Expression of VEGF and its receptors is regulated in eyes with intraocular tumours. J Pathol 1998;186:306-312.
12. Sheidow TG, Hooper PL, Crukley C, Young J, Heathcote JG: Expression of VEGF in uveal melanoma and its correlation with metastasis. Br J Ophthalmol 2000;84:750-756.
13. Boyd SR, Tan D, Bruce C, Gittos A, Neale MH, Hungerford JL, Charnock-Jones S, Cree IA: Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol 2002;86:448-452.
14. Boyd SR, Tan DS, de Souza L, Neale MH, Myatt NE, Alexander RA, Robb M, Hungerford JL, Cree IA: Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth. Br J Ophthalmol 2002;86:440-447.
15. Missotten GS, Notting IC, Schlingemann RO, Zijlmans HJ, Lau C, Eilers PH, Keunen JE, Jager MJ: Vascular endothelial growth factor-A in eyes with uveal melanoma. Arch Ophthalmol 2006;124:1428-1434.
16. Economou MA, Andersson S, Vasilcanu D, All-Ericsson C, Menu E, Girnita A, Girnita L, Axelson M, Seregard S, Larsson O: Oral picropodophyllin is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:2337-2342.
17. Notting IC, Missotten GS, Sijmons B, Boonman ZF, Keunen JE, van der Pluijm G: Angiogenesic profile of uveal melanoma. Curr Eye Res 2006;31:775-785.
18. Yang H, Cheng R, Liu G, Zhong Q, Li C, Cai W, Yang Z, Ma J, Yang X, Gao G: PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci 2009;100:2419-2425.
19. El Filali M, Missotten GS, Maat W, Ly LV, Luyten G P M, van der Velden PA, Jager MJ: Invest Ophthalmol Vis Sci 2010;51:2329-2337.
20. Ordonez JL, Paraoan L, Hiscott P, Gray D, Garcia-Finana M, Grierson I, Damato B: Differential expression of angioregulatory matricellular proteins in posterior uveal melanoma. Melanoma Res 2005;15:495-502.
21. Van der Velden PA, Zuidervaart W, Hurks MH, Pavey S, Ksander BR, Krijgsman E, Frants RR, Tensen C P, Willemze R, Jager MJ, Gruis NA: Expression profiling reveals that methylation of TIMP-3 is involved in uveal melanoma development. Int J Cancer 2003;106:472-479.
22. Sahin A, Kiratli H, Tezel GG, Soylemezoglu F, Bilgic S: Expression of vascular endothelial growth factor A, matrix metalloproteinase-9 and extravascular matrix patterns in iris and ciliary body melanomas. Ophthalmic Res 2007;39:40-44.
23. Canovas D, Rennie IG, Nichols CE, Sisley K: Local environmental influences on uveal melanoma. Vitreous humor promotes uveal melanoma invasion, whereas the aqueous can be inhibitory. Cancer 2008;112:1787-1794.
24. Crosby MB, Hubbard GB, Gallie BL, Grossniklaus HE: Anterior diffuse retinoblastoma: mutational analysis and immunofluorescence staining. Arch Pathol Lab Med 2009;133:1215-1218.
25. Rummelt V, Mehaffey MG, Campbell RJ, Pe'er J, Bentler SE, Woolson RF, Naumann GO, Folberg R: Microcirculation architecture of metastases from primary ciliary body and choroidal melanomas. Am J Ophthalmol 1998;126:303-305.
26. Folberg R, Rummelt V, Parys-van Ginderdeuren R, Hwang T, Woolson RF, Pe'er J, Gruman LM: The prognostic value of tumour blood vessel morphology in primary uveal melanoma. Ophthalmology 1993;100:1389-1398.
27. Bhat P, Jakobiec FA, Folberg R: Comparison of tumor-associated vasculatures in uveal and cutaneous melanomas. Semin Ophthalmol 2009;24:166-171.
28. Makitie T, Summanen P, Tarkkanen A, Kivela T: Microvascular loops and networks as prognostic indicators in choroidal and ciliary body melanomas. J Natl Cancer Inst 1999;91:359-367.
29. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner L M G, Pe'er J, Trent JM, Meltzer PS, Hendrix M J C: Vascular channel formation by human melanoma cells in vivo and in vitro; vascular mimicry. Am J Pathol 1999;155:739-752.
30. Clarijs R, Otte-Holler I, Ruiter DJ, de Waal R M W: Presence of a fluid-conducting meshwork in xenografted cutaneous and primary human uveal melanoma. Invest Ophthalmol Vis Sci 2002;43:912-918.
31. Shields CL, Shields JA, De Potter P: Patterns of indocyanine green videoangiography of choroidal tumors. Br J Ophthalmol 1995;79:237-245.
32. Clarijs R, Schalkwijk L, Ruiter DJ, de Waal RM: EMAP-II expression is associated with macrophage accumulation in primary uveal melanoma. Invest Ophthalmol Vis Sci 2003;44:1801-1806.
33. Makitie T, Summanen P, Tarkkanen A, Kivela T: Tumor-infiltrating macrophages (CD68+ cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001;42:1414-1421.
34. Maat W, Ly LV, Jordanova ES, de Wolff-Rouendaal D, Schalij-Delfos NE, Jager MJ: Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:505-510.
35. Archer DB: Doyne Lecture. Responses of retinal and choroidal vessels to ionizing radiation. Eye 1993;7:1-13.
36. Irvine AR, Woor IS: Radiation retinopathy as an experimental model for ischemic proliferative retinopathy and rubeosis iridis. Am J Ophthalmol 1987;103:790-797.
37. Horgan N, Shields CL, Mashayekhi A, Salazar PF, Materin MA, O'Reagan M, Shields JA: Periocular triamcinolone for prevention of macular edema after plaque radiotherapy of uveal melanoma: a randomized controlled trial. Arch Ophthalmol 2009;116:1383-1390.
38. Gunduz K, Shields CL, Shileds JA, Cater J, Freire JE, Brady LW: Radiation retinopathy following plaque radiotherapy for posterior uveal melanoma. Arch Ophthalmol 1999;117:609-614.
39. Horgan N, Shields CL, Mashayekhi A, Teixeira LF, Materin MA, Shields JA: Early macular morphological changes following plaque radiotherapy for uveal melanoma. Retina 2008;28:263-273.
40. Krema H, Simpson ER, Pavlin CJ, Payne D, Vasquez LM, McGowan H: Management of ciliary body melanoma with iodine-125 plaque therapy. Can J Ophthalmol 2009;44:395-400.
41. Boyd SR, Gittos A, Richter M, Hungerford JL, Errington RD, Cree IA: Proton beam therapy and iris neovascularisation in uveal melanoma. Eye 2006;20:832-836.
42. El Filali M, Homminga I, Maat W, Van der Velden PA, Jager MJ: Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. Mol Vis 2008;14:1752-1759.
43. Ijland SA, Jager MJ, Heijdra BM, Westphal JR, Peek R: Expression of angiogenic and immunosuppressive factors by uveal melanoma cell Lines. Melanoma Res 1999;9:445-450.
44. Ziemssen F, Voelker M, Altpeter E, Bartz-Schmidt KU, Gelisken F: Intravitreal bevacizumab treatment of radiation maculopathy due to brachytherapy in choroidal melanoma. Acta Ophthalmol 2007;85:579-580.
45. Jaissle GB, Ulmer A, Henke-Fahle S, Fierlbeck G, Bartz-Schmidt KU, Szurman P: Suppression of melanoma-associated neoangiogenesis by bevacizumab. Arch Dermatol 2008;144:525-527.
46. Bianciotto C, Shields CL, Kang B, Shields JA: Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy. Arch Ophthalmol 2008;126:578-579.
47. Vásquez LM, Somani S, Altomare F, Simpson ER: Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma. Can J Ophthalmol 2009;44:106-107.
48. Dunavoelgyi R, Zehetmayer M, Simader C, Schmidt-Erfurth U: Rapid improvement of radiation-induced neovascular glaucoma and exudative retinal detachment after a single intravitreal ranibizumab injection. Clin Exp Ophthalmol 2007;35:878-880.
49. Yang H, Xu Z, Luvone PM, Grossniklaus HE: Angiostatin decreases cell migration and VEGF to PEDF RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 2006;12:511-517.
50. 2b in patients with metastatic melanoma who failed prior treatment. Melanoma Res 2007;17:225-231.
51. Yang H, Akor C, Dithmar S, Grossniklaus HE: Lowdose adjuvant angiostatin decreases hepatic micrometastasis in murine ocular melanoma model. Mol Vis 2004;10:987-995.
52. Lee SY, Kim DK, Cho JH, Koh JY, Yoon YH: Inhibitory effect of bevacizumab on the angiogenesis and growth of retinoblastoma. Arch Ophthalmol 2008;126:953-958.
53. Yang H, Grossniklaus HE: Constitutive overexpression of pigment epithelium-derived factor inhibits ocular melanoma growth and metastasis. Invest Ophthalmol Vis Sci 2010;51:28-34.
54. AG mice. Invest Ophthalmol Vis Sci 2006;47:1264-1268.
55. Boutrid H, Pina Y, Cebulla CM, Feuer WJ, Lampidis TJ, Jockovich ME, Murray TG: Invest Ophthalmol Vis Sci 2009;50:5537-5543.
56. Boutrid H, Jockovich ME, Murray TG, Pina Y, Feuer WJ, Lampidis TJ, Cebulla CM: Targeting hypoxia, a novel treatment for advanced retinoblastoma. Invest Ophthalmol Vis Sci 2008;49:2799-2805.
57. Jia RB, Zhang YX, Zhou YX, Song X, Liu HY, Wang LZ, Luo M, Lu J, Ge SF, Fan XQ: VEGF-targeted RNA interference suppresses angiogenesis and tumor growth of retinoblastoma. Ophthalmic Res 2007;32:108-115.
58. Albini A, Fassini G, Nicolo M, Dell'Eva R, Vene R, Cammarota R, Barberis M, Noonan DM: Inhibition of a vascular ocular tumor growth by IL-12 gene transfer. Clin Exp Metastasis 2007;24:485-493.
59. Jager MJ: Angiogenesis in uveal melanoma. Ophthalmic Res 2006;38:248-250.
60. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, Kurihara T, Darland DC, Young MJ, D'Amore PA: Endogenous VEGF is required for visual function: evidence for a survival role on Müller cells and photoreceptors. PLoS One 2008;3:e3554.